TheraRadar
Data updated: Jun 17, 2026

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (calcium chloride)

Other Approved 1992-08-19

DELFLEX is a peritoneal dialysis solution indicated for patients with chronic renal failure. It is used to remove toxic substances, metabolic waste products, and excess body water that the kidneys can no longer filter. This solution is administered into the peritoneal cavity to help maintain electrolyte and fluid balance in patients undergoing CAPD (Continuous Ambulatory Peritoneal Dialysis) or CCPD (Continuous Cycling Peritoneal Dialysis).

Source: FDA Label • Fresenius Kabi

How DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER Works

DELFLEX works through the processes of diffusion and osmosis across the peritoneal membrane. The high concentration of Dextrose creates an osmotic gradient that draws excess water (ultrafiltration) from the patient's plasma into the peritoneal cavity. Simultaneously, metabolic waste products and toxins move from the blood into the dialysis solution via diffusion. The specific concentrations of electrolytes (sodium, chloride, magnesium, and calcium) help normalize the patient's serum electrolyte levels, while the absence of potassium allows for the removal of excess potassium from the body.

1
Indication
--
Phase 3 Trials
33
Years on Market

Details

Status
Prescription
First Approved
1992-08-19
Routes
INTRAPERITONEAL
Dosage Forms
SOLUTION

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER Approval History

1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
22 FDA actions from 1992 to 2021
Jan 2021 SUPPL
Label · Labeling
Mar 2016 SUPPL
Mfg · Manufacturing (CMC)
Jan 2015 SUPPL
Label · Labeling

What DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER Treats

2 indications

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Water deficiency
  • Electrolyte deficiency
Source: FDA Label

Drugs Similar to DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

3 of 19

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
CALCIUM CHLORIDE
2 shared
Pfizer
Shared indications:
Water deficiencyElectrolyte deficiency
CARDIOPLEGIC IN PLASTIC CONTAINER
CALCIUM CHLORIDE
2 shared
Baxter
Shared indications:
Water deficiencyElectrolyte deficiency
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
CALCIUM CHLORIDE
2 shared
Fresenius Kabi
Shared indications:
Electrolyte deficiencyWater deficiency

Fresenius Kabi's other novel FDA approvals

Other CDER-designated drugs from the same sponsor (2016–2025).

📋

Clinical Trial Registry

7 trials
Trial Sponsor ID Phase Status Title
NCT07550413 20042026 Ph 2 not yet recruiting Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section
NCT03772990 ICARUS 21/2019 Ph 4 completed Calcium Administration in Cardiac Surgery
NCT05027048 CALBLOC results posted 62206 MRTG-02-15-2022-Ansari, YIG-2020 Ph 3 completed Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
NCT04153435 COCA results posted 00002 2019-003387-46 Ph 2 completed Calcium for Out-of-Hospital Cardiac Arrest
NCT03867383 results posted 43076 Ph 1, Ph 2 completed Calcium Chloride for Prevention of Uterine Atony During Cesarean
NCT01941914 AA1310 Ph 1 completed Calcium Electroporation for the Treatment of Keloids
NCT00955266 results posted 2009-P-000052 Ph 4 terminated A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER is indicated for the treatment of Water deficiency; Electrolyte deficiency.

Track DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.